Top

Published in:

04-05-2022 | Respiratory Microbiota | EDITORIAL

Microbes and cancer: disease drivers, passengers, biomarkers, or therapeutics?

Author: Cynthia L. Sears

Published in: Cancer and Metastasis Reviews | Issue 2/2022

Excerpt

In the past 20 years, we have experienced a growing and innovative field investigating the vast human microbiota and its influence on health and disease pathogenesis. From this, we anticipate new prevention and therapeutic strategies for an increasing number of cancer types. In most cancers, microbiome research has flourished over the last 5–10 years. This is aptly illustrated in this issue of Cancer and Metastasis Reviews which contains important discussions of the findings and impact of microbiome research across colon, esophageal, pancreatic, and lung cancers, as well as melanoma, multiple myeloma, and hematopoietic malignancies. These papers discuss important cancer microbiome associations—local, systemic, and/or cancer-specific—and an early appreciation of mechanistic mediators focusing on immune responses, microbial metabolites, and/or the tumor microenvironment as well as responses to immunotherapy. …

O’Keefe, S. J., Li, J. V., Lahti, L., Ou, J., Carbonero, F., Mohammed, K., et al. (2015). Fat, fibre and cancer risk in African Americans and rural Africans. Nature Communications, 28(6), 6342. https://doi.org/10.1038/ncomms7342.CrossRef

He, Y., Wu, W., Zheng, H. M., Li, P., McDonald, D., Sheng, H. F., et al. (2018). Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nature Medicine, 24(10), 1532–1535. https://doi.org/10.1038/s41591-018-0164-x Erratum in: Nat Med. 2018 Sep 24.CrossRefPubMed

Thomas, A. M., Manghi, P., Asnicar, F., Pasolli, E., Armanini, F., Zolfo, M., et al. (2019). Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nature Medicine, 25(4), 667–678. https://doi.org/10.1038/s41591-019-0405-7 Erratum in: Nat Med.CrossRefPubMed

Vermeulen, R., Schymanski, E. L., Barabási, A. L., & Miller, G. W. (2020). The exposome and health: Where chemistry meets biology. Science, 367(6476), 392–396. https://doi.org/10.1126/science.aay3164.CrossRefPubMedPubMedCentral

Walter, J., Armet, A. M., Finlay, B. B., & Shanahan, F. (2020). Establishing or exaggerating causality for the gut microbiome: Lessons from human microbiota-associated rodents. Cell, 180(2), 221–232. https://doi.org/10.1016/j.cell.2019.12.025.CrossRefPubMed

Dethlefsen, L., & Relman, D. A. (2011). Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proceedings of the National Academy of Sciences of the United States of America, 108(Suppl 1), 4554–61. https://doi.org/10.1073/pnas.1000087107.CrossRefPubMed

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., Fidelle, M., Flament, C., Poirier-Colame, V., Opolon, P., Klein, C., Iribarren, K., Mondragón, L., Jacquelot, N., Qu, B., et al. (2018). Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science, 359(6371), 91–97. https://doi.org/10.1126/science.aan3706CrossRefPubMed

Mirzayi, C., Renson, A., Zohra, F., Elsafoury, S., Geistlinger, L., Kasselman, L. J., et al. (2021). Reporting guidelines for human microbiome research: The STORMS checklist. Nature Medicine, 27(11), 1885–1892. https://doi.org/10.1038/s41591-021-01552-x.CrossRefPubMedPubMedCentral

Chen, R. Y., Mostafa, I., Hibberd, M. C., Das, S., Mahfuz, M., Naila, N. N., et al. (2021). A microbiota-directed food intervention for undernourished children. New England Journal of Medicine, 384(16), 1517–1528. https://doi.org/10.1056/NEJMoa2023294.CrossRefPubMed

10.

Feuerstadt, P., Louie, T. J., Lashner, B., Wang, E. E. L., Diao, L., Bryant, J. A., et al. (2022). SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. New England Journal of Medicine, 386(3), 220–229. https://doi.org/10.1056/NEJMoa2106516.CrossRefPubMed

Title: Microbes and cancer: disease drivers, passengers, biomarkers, or therapeutics?
Author: Cynthia L. Sears
Publication date: 04-05-2022
Publisher: Springer US
Keywords: Respiratory Microbiota
Biomarkers
Published in: Cancer and Metastasis Reviews / Issue 2/2022
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-022-10035-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2022

The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor

Host-microbe interactions and outcomes in multiple myeloma and hematopoietic stem cell transplantation

Nanotechnology-aided advancement in the combating of cancer metastasis

Targeting lipid metabolism in cancer: neuroblastoma

Connecting the Human Microbiome and Pancreatic Cancer

Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer